New enzyme shot takes aim at Hard-to-Treat tumors
Disease control
Recruiting now
This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…
Phase: PHASE1, PHASE2 • Sponsor: Onchilles Pharma Inc • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC